RUBY - Dostarlimab for Primary Advanced or Recurrent Endometrial Cancer Last updated on May 1, 2024 Previous NRG GY018: Pembrolizumab in Advanced Endometrial Cancer Next PORTEC 2: Vaginal brachytherapy versus pelvic external beam radiotherapy for patients with endometrial cancer of high-intermediate risk
